Drugs / Yangxin Dawayimixike Honey Paste
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07314775 | Jan 2026 → Jul 2028 expected | atherosclerosis, hyperlipidemia | Xinjiang Uygur Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yangxin Dawayimixike Honey Paste | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07314775 ↗ |
| Route | Oral | “3 g bid po” NCT07314775 ↗ |